HRP20240935T1 - Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti - Google Patents
Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti Download PDFInfo
- Publication number
- HRP20240935T1 HRP20240935T1 HRP20240935TT HRP20240935T HRP20240935T1 HR P20240935 T1 HRP20240935 T1 HR P20240935T1 HR P20240935T T HRP20240935T T HR P20240935TT HR P20240935 T HRP20240935 T HR P20240935T HR P20240935 T1 HRP20240935 T1 HR P20240935T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyridazin
- tetramethylpiperidin
- triazolo
- phenol
- pyrazol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 52
- 208000023105 Huntington disease Diseases 0.000 title claims 3
- -1 5-(1H-pyrazol-4-yl)-2-[7-(2,2,6,6-tetramethylpiperidin-4-yl)-7H-imidazo[4,5-c]pyridazin-3-yl]phenol hydrochloride Chemical compound 0.000 claims 190
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 claims 33
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 21
- 239000000825 pharmaceutical preparation Substances 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- ZXRCAYWYTOIRQS-UHFFFAOYSA-N hydron;phenol;chloride Chemical compound Cl.OC1=CC=CC=C1 ZXRCAYWYTOIRQS-UHFFFAOYSA-N 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- JELQZSVKOONUKD-UHFFFAOYSA-N phenol dihydrochloride Chemical compound Cl.Cl.OC1=CC=CC=C1.OC1=CC=CC=C1 JELQZSVKOONUKD-UHFFFAOYSA-N 0.000 claims 8
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 8
- 150000003839 salts Chemical group 0.000 claims 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- ICZNVPJUHBURBG-UHFFFAOYSA-N 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]-5-(triazol-2-yl)phenol Chemical compound N1C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=CC=C(N3N=CC=N3)C=C1O)N=N2)(C)C ICZNVPJUHBURBG-UHFFFAOYSA-N 0.000 claims 3
- ORXRRLUUTYHCNI-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)N5N=CC=N5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)N5N=CC=N5)O)C.Cl ORXRRLUUTYHCNI-UHFFFAOYSA-N 0.000 claims 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 3
- YOUQXTMNMLEWCM-UHFFFAOYSA-N 2-(1-piperidin-4-ylpyrazolo[3,4-c]pyridazin-5-yl)-5-(1H-pyrazol-4-yl)phenol Chemical compound OC1=C(C=CC(=C1)C1=CNN=C1)C1=NN=C2N(N=CC2=C1)C1CCNCC1 YOUQXTMNMLEWCM-UHFFFAOYSA-N 0.000 claims 2
- FVXQGVZLCVMFLE-UHFFFAOYSA-N 2-(1-piperidin-4-ylpyrazolo[3,4-c]pyridazin-5-yl)-5-(1H-pyrazol-4-yl)phenol hydrochloride Chemical compound Cl.Oc1cc(ccc1-c1cc2cnn(C3CCNCC3)c2nn1)-c1cn[nH]c1 FVXQGVZLCVMFLE-UHFFFAOYSA-N 0.000 claims 2
- NJYKXOJRBBASGJ-UHFFFAOYSA-N 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]-5-(1,2,4-thiadiazol-5-yl)phenol Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=NC=NS1)O)(C)C)C NJYKXOJRBBASGJ-UHFFFAOYSA-N 0.000 claims 2
- NDQVGHCUUVQCTH-UHFFFAOYSA-N 2-[6-(methylamino)-7-(2,2,6,6-tetramethylpiperidin-4-yl)imidazo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol Chemical compound C1(NC(CC(C1)N1C2=C(N=C1NC)C=C(C1=CC=C(C=3C=NNC=3)C=C1O)N=N2)(C)C)(C)C NDQVGHCUUVQCTH-UHFFFAOYSA-N 0.000 claims 2
- WYXAJJZBFJBRKP-UHFFFAOYSA-N 2-fluoro-3-(1H-pyrazol-4-yl)-6-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]phenol Chemical compound N1C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=CC=C(C=3C=NNC=3)C(F)=C1O)N=N2)(C)C WYXAJJZBFJBRKP-UHFFFAOYSA-N 0.000 claims 2
- QFFQDEGMTBBEMV-UHFFFAOYSA-N 2-methyl-6-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]-1H-benzimidazol-5-ol Chemical compound C1(NC(CC(N2C3=NN=C(C4=C(O)C=C5NC(=NC5=C4)C)C=C3N=N2)C1)(C)C)(C)C QFFQDEGMTBBEMV-UHFFFAOYSA-N 0.000 claims 2
- VTBHBWBXALXSJK-UHFFFAOYSA-N 3-methyl-6-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]benzimidazol-5-ol Chemical compound N1C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=C(O)C=C3N(C=NC3=C1)C)N=N2)(C)C VTBHBWBXALXSJK-UHFFFAOYSA-N 0.000 claims 2
- NKDRVWDDKGMPCZ-UHFFFAOYSA-N 4-fluoro-2-(1H-pyrazol-4-yl)-5-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]phenol Chemical compound FC1=CC(=C(C=C1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)O)C=1C=NNC=1 NKDRVWDDKGMPCZ-UHFFFAOYSA-N 0.000 claims 2
- WGGHKOLLPVNZPN-UHFFFAOYSA-N 5-(1-methylpyrazol-4-yl)-2-[1-(2,2,6,6-tetramethylpiperidin-4-yl)pyrazolo[3,4-c]pyridazin-5-yl]phenol Chemical compound C1(C)(CC(N2C3=C(C=N2)C=C(C2=CC=C(C4=CN(N=C4)C)C=C2O)N=N3)CC(C)(C)N1)C WGGHKOLLPVNZPN-UHFFFAOYSA-N 0.000 claims 2
- JYDWYIQQANSETH-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[1-(2,2,6,6-tetramethylpiperidin-4-yl)imidazo[4,5-b]pyrazin-5-yl]phenol Chemical compound C1(NC(CC(C1)N1C2=NC=C(N=C2N=C1)C1=CC=C(C=2C=NNC=2)C=C1O)(C)C)(C)C JYDWYIQQANSETH-UHFFFAOYSA-N 0.000 claims 2
- YFWCCAXUEVEWBF-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[1-(2,2,6,6-tetramethylpiperidin-4-yl)pyrazolo[3,4-c]pyridazin-5-yl]phenol Chemical compound CC1(NC(CC(C1)N1C2=C(C=N1)C=C(C1=CC=C(C=3C=NNC=3)C=C1O)N=N2)(C)C)C YFWCCAXUEVEWBF-UHFFFAOYSA-N 0.000 claims 2
- UMAYQOIOMNDPOE-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]phenol Chemical compound C1(NC(CC(N2C3=NN=C(C=C3N=N2)C2=C(C=C(C=3C=NNC=3)C=C2)O)C1)(C)C)(C)C UMAYQOIOMNDPOE-UHFFFAOYSA-N 0.000 claims 2
- HODKQVFXRRLNPJ-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[5-(2,2,6,6-tetramethyl-1,3-dihydropyridin-4-yl)pyrrolo[2,3-b]pyrazin-2-yl]phenol Chemical compound N1C(CC(=CC1(C)C)N1C2=NC=C(N=C2C=C1)C1=CC=C(C2=CNN=C2)C=C1O)(C)C HODKQVFXRRLNPJ-UHFFFAOYSA-N 0.000 claims 2
- JECMMGGVMZYOIW-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[5-(2,2,6,6-tetramethylpiperidin-4-yl)pyrrolo[2,3-b]pyrazin-2-yl]phenol Chemical compound CC1(CC(N2C3=C(C=C2)N=C(C2=CC=C(C4=CNN=C4)C=C2O)C=N3)CC(C)(C)N1)C JECMMGGVMZYOIW-UHFFFAOYSA-N 0.000 claims 2
- GTKDDLZJVSMISF-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[7-(1,2,3,6-tetrahydropyridin-4-yl)-5H-pyrrolo[3,2-c]pyridazin-3-yl]phenol Chemical compound N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CN2)C=1CCNCC=1 GTKDDLZJVSMISF-UHFFFAOYSA-N 0.000 claims 2
- ZEZSKTLJQHOQSU-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[7-(2,2,6,6-tetramethyl-1,3-dihydropyridin-4-yl)thieno[3,2-c]pyridazin-3-yl]phenol Chemical compound N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CS2)C=1CC(NC(C=1)(C)C)(C)C ZEZSKTLJQHOQSU-UHFFFAOYSA-N 0.000 claims 2
- DTSRPRILCQRTJV-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[7-(2,2,6,6-tetramethylpiperidin-4-yl)-5,6-dihydropyrrolo[2,3-c]pyridazin-3-yl]phenol Chemical compound C1(C)(CC(N2CCC3=CC(C4=CC=C(C=5C=NNC=5)C=C4O)=NN=C23)CC(C)(C)N1)C DTSRPRILCQRTJV-UHFFFAOYSA-N 0.000 claims 2
- CZWBOKNESMYJDW-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[7-(2,2,6,6-tetramethylpiperidin-4-yl)imidazo[4,5-c]pyridazin-3-yl]phenol Chemical compound C1(NC(CC(C1)N1C2=C(N=C1)C=C(C1=CC=C(C=3C=NNC=3)C=C1O)N=N2)(C)C)(C)C CZWBOKNESMYJDW-UHFFFAOYSA-N 0.000 claims 2
- BRXVPPNQNVMBRK-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[7-(2,2,6,6-tetramethylpiperidin-4-yl)imidazo[4,5-c]pyridazin-3-yl]pyridin-3-ol Chemical compound C1(NC(CC(C1)N1C2=C(N=C1)C=C(C1=C(O)C=C(C3=CNN=C3)C=N1)N=N2)(C)C)(C)C BRXVPPNQNVMBRK-UHFFFAOYSA-N 0.000 claims 2
- XGLPDROYXHTXMK-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[7-(2,2,6,6-tetramethylpiperidin-4-yl)pyrrolo[2,3-c]pyridazin-3-yl]phenol Chemical compound C1(C)(NC(C)(C)CC(N2C=CC3=CC(C4=CC=C(C=5C=NNC=5)C=C4O)=NN=C23)C1)C XGLPDROYXHTXMK-UHFFFAOYSA-N 0.000 claims 2
- WBDSEOVLSQMPDX-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[7-(2,2,6,6-tetramethylpiperidin-4-yl)pyrrolo[2,3-c]pyridazin-3-yl]pyridin-3-ol Chemical compound N1C(CC(CC1(C)C)N1C2=C(C=C1)C=C(C1=C(O)C=C(C3=CNN=C3)C=N1)N=N2)(C)C WBDSEOVLSQMPDX-UHFFFAOYSA-N 0.000 claims 2
- FKTKNHQDCOLWNI-UHFFFAOYSA-N 5-(2-methyl-1,3-thiazol-5-yl)-2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]phenol Chemical compound CC=1SC(=CN=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C FKTKNHQDCOLWNI-UHFFFAOYSA-N 0.000 claims 2
- GIYSUKBTCIPXND-UHFFFAOYSA-N 5-(4-methylpyrazol-1-yl)-2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]phenol Chemical compound C1(C)(CC(N2C3=C(N=N2)C=C(C2=C(C=C(N4C=C(C=N4)C)C=C2)O)N=N3)CC(C)(C)N1)C GIYSUKBTCIPXND-UHFFFAOYSA-N 0.000 claims 2
- GXDFXOVBSJEHBS-UHFFFAOYSA-N 5-imidazol-1-yl-2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]phenol Chemical compound N1C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=CC=C(N3C=NC=C3)C=C1O)N=N2)(C)C GXDFXOVBSJEHBS-UHFFFAOYSA-N 0.000 claims 2
- XBRAKTVAHFZAIT-UHFFFAOYSA-N 5-pyrazol-1-yl-2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]phenol Chemical compound N1(N=CC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C XBRAKTVAHFZAIT-UHFFFAOYSA-N 0.000 claims 2
- BQSBAHQXPBCOHL-UHFFFAOYSA-N 6-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]quinolin-7-ol Chemical compound N1C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=C(O)C=C3N=CC=CC3=C1)N=N2)(C)C BQSBAHQXPBCOHL-UHFFFAOYSA-N 0.000 claims 2
- HCHBPWYLYODRFT-UHFFFAOYSA-N 6-[3-hydroxy-4-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]phenyl]pyridin-3-ol Chemical compound CC1(NC(C)(C)CC(N2C3=C(N=N2)C=C(C2=CC=C(C4=CC=C(O)C=N4)C=C2O)N=N3)C1)C HCHBPWYLYODRFT-UHFFFAOYSA-N 0.000 claims 2
- FWZMSKSFXHUBSW-UHFFFAOYSA-N 6-[3-hydroxy-4-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]phenyl]pyridin-3-ol dihydrochloride Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NC=C(C=C5)O)O)C.Cl.Cl FWZMSKSFXHUBSW-UHFFFAOYSA-N 0.000 claims 2
- KANAKZDOZBCHQI-UHFFFAOYSA-N 6-[7-(1H-pyrazol-4-yl)-2H-benzotriazol-4-yl]-3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazine Chemical compound N1C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=CC=C(C=3C=NNC=3)C=3N=NNC1=3)N=N2)(C)C KANAKZDOZBCHQI-UHFFFAOYSA-N 0.000 claims 2
- LKKVVUAIJFFYKR-UHFFFAOYSA-N Br.CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C=1C=C2C=CC=NC2=CC=1O)(C)C)C Chemical compound Br.CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C=1C=C2C=CC=NC2=CC=1O)(C)C)C LKKVVUAIJFFYKR-UHFFFAOYSA-N 0.000 claims 2
- WLVVXZGHMCKLHT-UHFFFAOYSA-N Br.FC1=CC(=C(C=C1C1=CC=C(C=C1)O)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound Br.FC1=CC(=C(C=C1C1=CC=C(C=C1)O)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C WLVVXZGHMCKLHT-UHFFFAOYSA-N 0.000 claims 2
- PXVVRAVHOUCNOQ-UHFFFAOYSA-N BrC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound BrC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C PXVVRAVHOUCNOQ-UHFFFAOYSA-N 0.000 claims 2
- RMBKEKVHYKCBQU-UHFFFAOYSA-N C(=O)OC1=C(C=CC(=C1)C1=NC=C(C=C1)OC(F)F)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C(=O)OC1=C(C=CC(=C1)C1=NC=C(C=C1)OC(F)F)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C RMBKEKVHYKCBQU-UHFFFAOYSA-N 0.000 claims 2
- KTAQHPPSQLMJJW-UHFFFAOYSA-N C(=O)OC1=C(C=CC(=C1)C=1OC=CN=1)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C(=O)OC1=C(C=CC(=C1)C=1OC=CN=1)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C KTAQHPPSQLMJJW-UHFFFAOYSA-N 0.000 claims 2
- IETUBBFAMCEKDY-UHFFFAOYSA-N C(C)N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C(C)N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C IETUBBFAMCEKDY-UHFFFAOYSA-N 0.000 claims 2
- NRAVMEBVFBHKNZ-UHFFFAOYSA-N C(C)N1N=CC(=C1F)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C(C)N1N=CC(=C1F)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C NRAVMEBVFBHKNZ-UHFFFAOYSA-N 0.000 claims 2
- KHTWIGWWVCHDGM-UHFFFAOYSA-N C(C)NC1=NC2=C(N=NC(=C2)C2=C(C=C(C=C2)C=2C=NNC=2)O)N1C1CC(NC(C1)(C)C)(C)C Chemical compound C(C)NC1=NC2=C(N=NC(=C2)C2=C(C=C(C=C2)C=2C=NNC=2)O)N1C1CC(NC(C1)(C)C)(C)C KHTWIGWWVCHDGM-UHFFFAOYSA-N 0.000 claims 2
- JHDYRZFBNRBQPV-UHFFFAOYSA-N C(C)OC1=CC(=NC=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C(C)OC1=CC(=NC=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C JHDYRZFBNRBQPV-UHFFFAOYSA-N 0.000 claims 2
- KHAZRTSCDAEECH-UHFFFAOYSA-N C(C)OC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C(C)OC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C KHAZRTSCDAEECH-UHFFFAOYSA-N 0.000 claims 2
- XXNQVQXOGYTQAO-UHFFFAOYSA-N C(CC)N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C(CC)N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C XXNQVQXOGYTQAO-UHFFFAOYSA-N 0.000 claims 2
- AQEDLCXPALRUPH-VPYROQPTSA-N C(N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)([2H])([2H])[2H] Chemical compound C(N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)([2H])([2H])[2H] AQEDLCXPALRUPH-VPYROQPTSA-N 0.000 claims 2
- WGGHKOLLPVNZPN-VPYROQPTSA-N C(N1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C)([2H])([2H])[2H] Chemical compound C(N1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C)([2H])([2H])[2H] WGGHKOLLPVNZPN-VPYROQPTSA-N 0.000 claims 2
- AASTXZYIDCCVHJ-UHFFFAOYSA-N C1(C)(CC(N2C3=C(C=C2)N=C(C2=CC(F)=C(C4=CNN=C4)C=C2F)C=N3)CC(C)(C)N1)C Chemical compound C1(C)(CC(N2C3=C(C=C2)N=C(C2=CC(F)=C(C4=CNN=C4)C=C2F)C=N3)CC(C)(C)N1)C AASTXZYIDCCVHJ-UHFFFAOYSA-N 0.000 claims 2
- ZMKXJPXWSNQLIU-UHFFFAOYSA-N C1(CC1)N1C(C=C(C=C1)C1=CC(=C(C=C1)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)O)=O Chemical compound C1(CC1)N1C(C=C(C=C1)C1=CC(=C(C=C1)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)O)=O ZMKXJPXWSNQLIU-UHFFFAOYSA-N 0.000 claims 2
- MDLNGIZCASBHMN-UHFFFAOYSA-N C1(NC(CC(C1)N1C2=NN=C(C=C2N=N1)C1=CC=C(C=2C=CNC=2)C=C1O)(C)C)(C)C Chemical compound C1(NC(CC(C1)N1C2=NN=C(C=C2N=N1)C1=CC=C(C=2C=CNC=2)C=C1O)(C)C)(C)C MDLNGIZCASBHMN-UHFFFAOYSA-N 0.000 claims 2
- UFKJUQIDZGBEHX-UHFFFAOYSA-N C1(NC(CC(N2C3=C(N=N2)C=C(C2=CC(F)=C(C=4C=NNC=4)C=C2F)N=N3)C1)(C)C)(C)C Chemical compound C1(NC(CC(N2C3=C(N=N2)C=C(C2=CC(F)=C(C=4C=NNC=4)C=C2F)N=N3)C1)(C)C)(C)C UFKJUQIDZGBEHX-UHFFFAOYSA-N 0.000 claims 2
- AZMSBIPXIFBYMA-UHFFFAOYSA-N C12C=C(CC(CC1)N2)C1=CNC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O Chemical compound C12C=C(CC(CC1)N2)C1=CNC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O AZMSBIPXIFBYMA-UHFFFAOYSA-N 0.000 claims 2
- QJXUMDJCCKAJPF-UHFFFAOYSA-N C12C=C(CC(CC1)N2)C1=CSC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O Chemical compound C12C=C(CC(CC1)N2)C1=CSC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O QJXUMDJCCKAJPF-UHFFFAOYSA-N 0.000 claims 2
- XBNQXTTZXIGHQO-UHFFFAOYSA-N C12COCC(C=C(C1)C1=CNC3=C1N=NC(=C3)C1=C(C=C(C=C1)C=1C=NNC=1)O)N2 Chemical compound C12COCC(C=C(C1)C1=CNC3=C1N=NC(=C3)C1=C(C=C(C=C1)C=1C=NNC=1)O)N2 XBNQXTTZXIGHQO-UHFFFAOYSA-N 0.000 claims 2
- BXDQEBYEDBZCFL-UHFFFAOYSA-N C12COCC(C=C(C1)C1=CSC3=C1N=NC(=C3)C1=C(C=C(C=C1)C=1C=NNC=1)O)N2 Chemical compound C12COCC(C=C(C1)C1=CSC3=C1N=NC(=C3)C1=C(C=C(C=C1)C=1C=NNC=1)O)N2 BXDQEBYEDBZCFL-UHFFFAOYSA-N 0.000 claims 2
- AYUOXUYOPDONIA-UHFFFAOYSA-N C12COCC(CC(C1)C1=CNC3=C1N=NC(C1=CC=C(C=4C=NNC=4)C=C1O)=C3)N2 Chemical compound C12COCC(CC(C1)C1=CNC3=C1N=NC(C1=CC=C(C=4C=NNC=4)C=C1O)=C3)N2 AYUOXUYOPDONIA-UHFFFAOYSA-N 0.000 claims 2
- DMSDXTCCTHPVTI-UHFFFAOYSA-N C1CN(CCN1)C1=CNC2=C1N=NC(=C2)C1=CC=C(C=2C=NNC=2)C=C1O Chemical compound C1CN(CCN1)C1=CNC2=C1N=NC(=C2)C1=CC=C(C=2C=NNC=2)C=C1O DMSDXTCCTHPVTI-UHFFFAOYSA-N 0.000 claims 2
- CXMDEHRGUNSXHR-UHFFFAOYSA-N C=1N=CN2C=1C=C(C=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C=1N=CN2C=1C=C(C=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C CXMDEHRGUNSXHR-UHFFFAOYSA-N 0.000 claims 2
- IEZREAUMRJSMTC-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CC=NC=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CC=NC=C5)O)C.Cl IEZREAUMRJSMTC-UHFFFAOYSA-N 0.000 claims 2
- CJSNRGRIMPZUIK-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CN=CC=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CN=CC=C5)O)C.Cl CJSNRGRIMPZUIK-UHFFFAOYSA-N 0.000 claims 2
- GITWIISOXLUAER-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=NN(C=C5)C)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=NN(C=C5)C)O)C.Cl GITWIISOXLUAER-UHFFFAOYSA-N 0.000 claims 2
- VMLUWDSZNIOKLA-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)N5N=CC=N5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)N5N=CC=N5)O)C.Cl VMLUWDSZNIOKLA-UHFFFAOYSA-N 0.000 claims 2
- OVPVUCKYVNAFEN-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C(=C(C=C4)C5=CNN=C5)F)O)C.Cl.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C(=C(C=C4)C5=CNN=C5)F)O)C.Cl.Cl OVPVUCKYVNAFEN-UHFFFAOYSA-N 0.000 claims 2
- UNPIMBQCABESRN-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CC(=NC=C5)C(F)(F)F)O)C.Cl.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CC(=NC=C5)C(F)(F)F)O)C.Cl.Cl UNPIMBQCABESRN-UHFFFAOYSA-N 0.000 claims 2
- JSHFCOUDIJCPEG-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CC6=NC=NN6C=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CC6=NC=NN6C=C5)O)C.Cl JSHFCOUDIJCPEG-UHFFFAOYSA-N 0.000 claims 2
- CYRDUAAZDRATQT-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CN6C=CN=C6N=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CN6C=CN=C6N=C5)O)C.Cl CYRDUAAZDRATQT-UHFFFAOYSA-N 0.000 claims 2
- HRJAULMCRJPELB-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CN=NC=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CN=NC=C5)O)C.Cl HRJAULMCRJPELB-UHFFFAOYSA-N 0.000 claims 2
- WCHKOTOJCYHTLF-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NC=NC=C5)O)C.Cl.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NC=NC=C5)O)C.Cl.Cl WCHKOTOJCYHTLF-UHFFFAOYSA-N 0.000 claims 2
- WGMYPATXGPWPEQ-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NC=NS5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NC=NS5)O)C.Cl WGMYPATXGPWPEQ-UHFFFAOYSA-N 0.000 claims 2
- QXZZNERSSNMHDQ-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NN6C=CN=C6C=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NN6C=CN=C6C=C5)O)C.Cl QXZZNERSSNMHDQ-UHFFFAOYSA-N 0.000 claims 2
- KYWXKZFVBMQRQY-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NN6C=NN=C6C=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NN6C=NN=C6C=C5)O)C.Cl KYWXKZFVBMQRQY-UHFFFAOYSA-N 0.000 claims 2
- KQQVADAHESEGTK-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=CC=2C1=NN=C(C=2)C1=C(C=C(C=C1)N1N=CC=N1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=CC=2C1=NN=C(C=2)C1=C(C=C(C=C1)N1N=CC=N1)O)(C)C)C KQQVADAHESEGTK-UHFFFAOYSA-N 0.000 claims 2
- CSBJUXPHLKVWSL-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC(=NC=C1)C(F)(F)F)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC(=NC=C1)C(F)(F)F)O)(C)C)C CSBJUXPHLKVWSL-UHFFFAOYSA-N 0.000 claims 2
- JXGOYLVUPONQNJ-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC2=C(C=N1)NN=N2)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC2=C(C=N1)NN=N2)O)(C)C)C JXGOYLVUPONQNJ-UHFFFAOYSA-N 0.000 claims 2
- LLUUWAIXIGURPB-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=2N(C=C1)N=CN=2)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=2N(C=C1)N=CN=2)O)(C)C)C LLUUWAIXIGURPB-UHFFFAOYSA-N 0.000 claims 2
- QRPNFWFAESPZOV-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=2N(C=C1)N=NC=2)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=2N(C=C1)N=NC=2)O)(C)C)C QRPNFWFAESPZOV-UHFFFAOYSA-N 0.000 claims 2
- SJJFQXDPRPTDDW-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=C(C=C1)O)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=C(C=C1)O)O)(C)C)C SJJFQXDPRPTDDW-UHFFFAOYSA-N 0.000 claims 2
- CEDDLRANFAVQAB-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=C2C(=N1)N=NN2)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=C2C(=N1)N=NN2)O)(C)C)C CEDDLRANFAVQAB-UHFFFAOYSA-N 0.000 claims 2
- OVGMNSUGWLZSDU-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CN=CS1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CN=CS1)O)(C)C)C OVGMNSUGWLZSDU-UHFFFAOYSA-N 0.000 claims 2
- XTEXURNNNAMPIJ-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CSC=C1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CSC=C1)O)(C)C)C XTEXURNNNAMPIJ-UHFFFAOYSA-N 0.000 claims 2
- WLFWIKNAYJZCCO-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C(=NNC=1)C(F)(F)F)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C(=NNC=1)C(F)(F)F)O)(C)C)C WLFWIKNAYJZCCO-UHFFFAOYSA-N 0.000 claims 2
- NOQKNJTXSIATAL-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=C2C(=NC=1)N=NN2)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=C2C(=NC=1)N=NN2)O)(C)C)C NOQKNJTXSIATAL-UHFFFAOYSA-N 0.000 claims 2
- YBSZMQWTRMGMQI-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=CC=2N(N=1)C=NN=2)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=CC=2N(N=1)C=NN=2)O)(C)C)C YBSZMQWTRMGMQI-UHFFFAOYSA-N 0.000 claims 2
- UJESCMOWHXNYFU-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1N=NNC=1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1N=NNC=1)O)(C)C)C UJESCMOWHXNYFU-UHFFFAOYSA-N 0.000 claims 2
- DXNAKRLUCGVJEU-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1SC=CN=1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1SC=CN=1)O)(C)C)C DXNAKRLUCGVJEU-UHFFFAOYSA-N 0.000 claims 2
- BSCBHDGQVZTZLE-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1SC=NN=1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1SC=NN=1)O)(C)C)C BSCBHDGQVZTZLE-UHFFFAOYSA-N 0.000 claims 2
- FNCQBOLCGFCVSG-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)N1C=NN=C1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)N1C=NN=C1)O)(C)C)C FNCQBOLCGFCVSG-UHFFFAOYSA-N 0.000 claims 2
- JJEBEFOKMRUUFQ-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)N1N=CN=C1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)N1N=CN=C1)O)(C)C)C JJEBEFOKMRUUFQ-UHFFFAOYSA-N 0.000 claims 2
- CQWSCHMMQKDQGJ-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)N1N=NC=C1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)N1N=NC=C1)O)(C)C)C CQWSCHMMQKDQGJ-UHFFFAOYSA-N 0.000 claims 2
- BJZXKFHEXMGQKP-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C=1C=C2C=NNC2=CC=1O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C=1C=C2C=NNC2=CC=1O)(C)C)C BJZXKFHEXMGQKP-UHFFFAOYSA-N 0.000 claims 2
- CDCSEJKBOILEBA-UHFFFAOYSA-N CC1=CC=NN1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC1=CC=NN1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C CDCSEJKBOILEBA-UHFFFAOYSA-N 0.000 claims 2
- GRFUWTZWUSNGQI-UHFFFAOYSA-N CC1=CN=C(S1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC1=CN=C(S1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C GRFUWTZWUSNGQI-UHFFFAOYSA-N 0.000 claims 2
- XRUPPQILLKVLJT-UHFFFAOYSA-N CC1=NC2=C(N=NC(=C2)C2=C(C=C(C=C2)C=2C=NNC=2)O)N1C1CC(NC(C1)(C)C)(C)C Chemical compound CC1=NC2=C(N=NC(=C2)C2=C(C=C(C=C2)C=2C=NNC=2)O)N1C1CC(NC(C1)(C)C)(C)C XRUPPQILLKVLJT-UHFFFAOYSA-N 0.000 claims 2
- XJEYOUGWYYHRSH-UHFFFAOYSA-N CC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C XJEYOUGWYYHRSH-UHFFFAOYSA-N 0.000 claims 2
- PYQQNCSCXQFGMO-UHFFFAOYSA-N CC1=NN(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC1=NN(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C PYQQNCSCXQFGMO-UHFFFAOYSA-N 0.000 claims 2
- YLJHBGQTZFIKII-UHFFFAOYSA-N CC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C YLJHBGQTZFIKII-UHFFFAOYSA-N 0.000 claims 2
- KWFRWGMXKRKGSA-UHFFFAOYSA-N CC1=NSC(=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC1=NSC(=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C KWFRWGMXKRKGSA-UHFFFAOYSA-N 0.000 claims 2
- PNZJHPXANGNSQF-UHFFFAOYSA-N CC=1N(C=C(N=1)C)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC=1N(C=C(N=1)C)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C PNZJHPXANGNSQF-UHFFFAOYSA-N 0.000 claims 2
- NGEDKDZTTVTODN-UHFFFAOYSA-N CC=1N=CN(C=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC=1N=CN(C=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C NGEDKDZTTVTODN-UHFFFAOYSA-N 0.000 claims 2
- COKAZEDTDINQIP-UHFFFAOYSA-N CC=1OC(=CN=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC=1OC(=CN=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C COKAZEDTDINQIP-UHFFFAOYSA-N 0.000 claims 2
- NXNRBQYYWJEGKU-UHFFFAOYSA-N CCOC1=NC=CC(=C1)C2=CC(=C(C=C2)C3=NN=C4C(=C3)N=NN4C5CC(NC(C5)(C)C)(C)C)O.Cl Chemical compound CCOC1=NC=CC(=C1)C2=CC(=C(C=C2)C3=NN=C4C(=C3)N=NN4C5CC(NC(C5)(C)C)(C)C)O.Cl NXNRBQYYWJEGKU-UHFFFAOYSA-N 0.000 claims 2
- NXEPJRQTRBYXAO-UHFFFAOYSA-N CN(C1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C Chemical compound CN(C1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C NXEPJRQTRBYXAO-UHFFFAOYSA-N 0.000 claims 2
- QTPNFWZMBNTULA-UHFFFAOYSA-N CN1N=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CN1N=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C QTPNFWZMBNTULA-UHFFFAOYSA-N 0.000 claims 2
- JENUBTCRIWMELY-UHFFFAOYSA-N CN1N=C(C=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C Chemical compound CN1N=C(C=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C JENUBTCRIWMELY-UHFFFAOYSA-N 0.000 claims 2
- AQEDLCXPALRUPH-UHFFFAOYSA-N CN1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CN1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C AQEDLCXPALRUPH-UHFFFAOYSA-N 0.000 claims 2
- JNKSCAAIDAPBDP-UHFFFAOYSA-N CN1N=CC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CN1N=CC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C JNKSCAAIDAPBDP-UHFFFAOYSA-N 0.000 claims 2
- AJVQSOIQYABCEJ-UHFFFAOYSA-N CN1N=NC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CN1N=NC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C AJVQSOIQYABCEJ-UHFFFAOYSA-N 0.000 claims 2
- HAHUVWOHNUHKIM-UHFFFAOYSA-N CNC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CNC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C HAHUVWOHNUHKIM-UHFFFAOYSA-N 0.000 claims 2
- ZNSFSXYSTJPUPK-UHFFFAOYSA-N COC1=NC(=NC=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound COC1=NC(=NC=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C ZNSFSXYSTJPUPK-UHFFFAOYSA-N 0.000 claims 2
- XXVGQLCBMSURJO-UHFFFAOYSA-N COC1=NC2=C(N=NC(=C2)C2=C(C=C(C=C2)C=2C=NNC=2)O)N1C1CC(NC(C1)(C)C)(C)C Chemical compound COC1=NC2=C(N=NC(=C2)C2=C(C=C(C=C2)C=2C=NNC=2)O)N1C1CC(NC(C1)(C)C)(C)C XXVGQLCBMSURJO-UHFFFAOYSA-N 0.000 claims 2
- DZRVKVKNDDGPHA-UHFFFAOYSA-N COC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound COC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C DZRVKVKNDDGPHA-UHFFFAOYSA-N 0.000 claims 2
- MSLFSJYSLDOETC-UHFFFAOYSA-N COC1=NC=CC(=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound COC1=NC=CC(=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C MSLFSJYSLDOETC-UHFFFAOYSA-N 0.000 claims 2
- MKKLUEGHXQUPTH-UHFFFAOYSA-N COC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound COC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C MKKLUEGHXQUPTH-UHFFFAOYSA-N 0.000 claims 2
- OBCDNXOFZPDSIO-GJDMYPNDSA-N C[C@]12CC(C[C@](CC1)(N2)C)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O Chemical compound C[C@]12CC(C[C@](CC1)(N2)C)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O OBCDNXOFZPDSIO-GJDMYPNDSA-N 0.000 claims 2
- DUVNLSMHNGFZCZ-UHFFFAOYSA-N Cl.Cl.CN1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C Chemical compound Cl.Cl.CN1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C DUVNLSMHNGFZCZ-UHFFFAOYSA-N 0.000 claims 2
- OCDFZPMFFCLFBC-UHFFFAOYSA-N Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CO2)C=1CC(NC(C=1)(C)C)(C)C Chemical compound Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CO2)C=1CC(NC(C=1)(C)C)(C)C OCDFZPMFFCLFBC-UHFFFAOYSA-N 0.000 claims 2
- BWEIDMONBZWFMT-UHFFFAOYSA-N Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CS2)C=1CC(NC(C=1)(C)C)(C)C Chemical compound Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CS2)C=1CC(NC(C=1)(C)C)(C)C BWEIDMONBZWFMT-UHFFFAOYSA-N 0.000 claims 2
- ZZOUGQPJPMWXBA-UHFFFAOYSA-N Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(C=C2)C1CC(NC(C1)(C)C)(C)C Chemical compound Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(C=C2)C1CC(NC(C1)(C)C)(C)C ZZOUGQPJPMWXBA-UHFFFAOYSA-N 0.000 claims 2
- COYVNWOAAHCHPR-UHFFFAOYSA-N Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(CC2)C1CC(NC(C1)(C)C)(C)C Chemical compound Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(CC2)C1CC(NC(C1)(C)C)(C)C COYVNWOAAHCHPR-UHFFFAOYSA-N 0.000 claims 2
- WRXNKRJISZUEMS-UHFFFAOYSA-N Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C Chemical compound Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C WRXNKRJISZUEMS-UHFFFAOYSA-N 0.000 claims 2
- LAFQILYFLYVGEI-UHFFFAOYSA-N Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1N=C2C(=NC=1)N(C=C2)C1CC(NC(C1)(C)C)(C)C Chemical compound Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1N=C2C(=NC=1)N(C=C2)C1CC(NC(C1)(C)C)(C)C LAFQILYFLYVGEI-UHFFFAOYSA-N 0.000 claims 2
- LNBVZAKASREDEA-UHFFFAOYSA-N Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1N=C2C(=NC=1)N(C=C2)C=1CC(NC(C=1)(C)C)(C)C Chemical compound Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1N=C2C(=NC=1)N(C=C2)C=1CC(NC(C=1)(C)C)(C)C LNBVZAKASREDEA-UHFFFAOYSA-N 0.000 claims 2
- QGWFESDUZREXAI-UHFFFAOYSA-N Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1N=C2C(=NC=1)N(C=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound Cl.N1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1N=C2C(=NC=1)N(C=N2)C1CC(NC(C1)(C)C)(C)C QGWFESDUZREXAI-UHFFFAOYSA-N 0.000 claims 2
- MJHHZVNDJRXUOT-UHFFFAOYSA-N ClC1=CC(=C(C=C1C=1C=NNC=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound ClC1=CC(=C(C=C1C=1C=NNC=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C MJHHZVNDJRXUOT-UHFFFAOYSA-N 0.000 claims 2
- BPDAMOXLQFMMFU-UHFFFAOYSA-N ClC1=NN(C=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C Chemical compound ClC1=NN(C=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C BPDAMOXLQFMMFU-UHFFFAOYSA-N 0.000 claims 2
- VVZIWNAJUVKWTB-UHFFFAOYSA-N ClC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound ClC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C VVZIWNAJUVKWTB-UHFFFAOYSA-N 0.000 claims 2
- KILHLZWQOGMXCM-UHFFFAOYSA-N FC(N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)F Chemical compound FC(N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)F KILHLZWQOGMXCM-UHFFFAOYSA-N 0.000 claims 2
- QIVFOZBOURRSAK-UHFFFAOYSA-N FC(OC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)F Chemical compound FC(OC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)F QIVFOZBOURRSAK-UHFFFAOYSA-N 0.000 claims 2
- WCXRTNTVHFKOKQ-UHFFFAOYSA-N FC(OC=1C=CC(=NC=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)F Chemical compound FC(OC=1C=CC(=NC=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)F WCXRTNTVHFKOKQ-UHFFFAOYSA-N 0.000 claims 2
- SXOWGTNFCLHLGC-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)O)C1=CC(N(C=C1)C)=O Chemical compound FC1=C(C=C(C(=C1)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)O)C1=CC(N(C=C1)C)=O SXOWGTNFCLHLGC-UHFFFAOYSA-N 0.000 claims 2
- PEUYIDPFKFFJSS-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C=1C=NNC=1)F)C1=CC2=C(N=N1)N(C(=N2)C)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=C(C=C(C(=C1)C=1C=NNC=1)F)C1=CC2=C(N=N1)N(C(=N2)C)C1CC(NC(C1)(C)C)(C)C PEUYIDPFKFFJSS-UHFFFAOYSA-N 0.000 claims 2
- YROZHUOYTYNDFI-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C=1C=NNC=1)F)C1=CC2=C(N=N1)N(C=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=C(C=C(C(=C1)C=1C=NNC=1)F)C1=CC2=C(N=N1)N(C=N2)C1CC(NC(C1)(C)C)(C)C YROZHUOYTYNDFI-UHFFFAOYSA-N 0.000 claims 2
- GKFOUMOPPPDJMQ-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C=1C=NNC=1)F)C=1N=C2C(=NC=1)N(C=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=C(C=C(C(=C1)C=1C=NNC=1)F)C=1N=C2C(=NC=1)N(C=N2)C1CC(NC(C1)(C)C)(C)C GKFOUMOPPPDJMQ-UHFFFAOYSA-N 0.000 claims 2
- BAVYCCNBKZJTQG-UHFFFAOYSA-N FC1=C(C=CC(=C1F)C=1C=NNC=1)C1=CC2=C(N=N1)N(CC2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=C(C=CC(=C1F)C=1C=NNC=1)C1=CC2=C(N=N1)N(CC2)C1CC(NC(C1)(C)C)(C)C BAVYCCNBKZJTQG-UHFFFAOYSA-N 0.000 claims 2
- YWNIDMAQAVKKHU-UHFFFAOYSA-N FC1=C(C=CC(=C1F)C=1C=NNC=1)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=C(C=CC(=C1F)C=1C=NNC=1)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C YWNIDMAQAVKKHU-UHFFFAOYSA-N 0.000 claims 2
- WJCXRFVILGBHNX-UHFFFAOYSA-N FC1=C(C=NN1C)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=C(C=NN1C)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C WJCXRFVILGBHNX-UHFFFAOYSA-N 0.000 claims 2
- GDAHALNLMUDALK-UHFFFAOYSA-N FC1=CC(=C(C=C1C1=CC=C(C=C1)O)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=CC(=C(C=C1C1=CC=C(C=C1)O)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C GDAHALNLMUDALK-UHFFFAOYSA-N 0.000 claims 2
- HQDOVDQLIOLPGI-UHFFFAOYSA-N FC1=CC(=C(C=C1C1=CC=NC=C1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=CC(=C(C=C1C1=CC=NC=C1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C HQDOVDQLIOLPGI-UHFFFAOYSA-N 0.000 claims 2
- KGIAIPDHAKHOHT-UHFFFAOYSA-N FC1=CC(=C(C=C1C=1C=NN(C=1)C)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=CC(=C(C=C1C=1C=NN(C=1)C)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C KGIAIPDHAKHOHT-UHFFFAOYSA-N 0.000 claims 2
- BXVHKSKPRQEOKB-UHFFFAOYSA-N FC1=CC(=C(C=C1C=1C=NNC=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=CC(=C(C=C1C=1C=NNC=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C BXVHKSKPRQEOKB-UHFFFAOYSA-N 0.000 claims 2
- AFHOJSKWIMYDGZ-UHFFFAOYSA-N FC1=CC(=CC=2NN=NC=21)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=CC(=CC=2NN=NC=21)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C AFHOJSKWIMYDGZ-UHFFFAOYSA-N 0.000 claims 2
- INOHGYPYCHKPBM-UHFFFAOYSA-N FC1=NN(C=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C Chemical compound FC1=NN(C=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C INOHGYPYCHKPBM-UHFFFAOYSA-N 0.000 claims 2
- FIEBCNQTCOVUFG-UHFFFAOYSA-N FC1=NN(C=C1C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C)C Chemical compound FC1=NN(C=C1C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C)C FIEBCNQTCOVUFG-UHFFFAOYSA-N 0.000 claims 2
- UECIEINXBYIBJE-UHFFFAOYSA-N FC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C UECIEINXBYIBJE-UHFFFAOYSA-N 0.000 claims 2
- ZBELULYUWBAQOO-WMZOPIPTSA-N FC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F Chemical compound FC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)[C@@H]1[C@@H](C(NC(C1)(C)C)(C)C)F ZBELULYUWBAQOO-WMZOPIPTSA-N 0.000 claims 2
- WRXQARSSSFRRGF-UHFFFAOYSA-N FC1=NNC=C1C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=NNC=C1C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C WRXQARSSSFRRGF-UHFFFAOYSA-N 0.000 claims 2
- NWWJTIJLYUSOCM-UHFFFAOYSA-N FC=1C(=C(C=C(C=1)C=1C=NNC=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC=1C(=C(C=C(C=1)C=1C=NNC=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C NWWJTIJLYUSOCM-UHFFFAOYSA-N 0.000 claims 2
- GWFQXHPQZZMPQA-UHFFFAOYSA-N FC=1C=NC=CC=1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC=1C=NC=CC=1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C GWFQXHPQZZMPQA-UHFFFAOYSA-N 0.000 claims 2
- ZFQVDORKHFGMFW-UHFFFAOYSA-N FC=1N=C(SC=1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C Chemical compound FC=1N=C(SC=1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C ZFQVDORKHFGMFW-UHFFFAOYSA-N 0.000 claims 2
- JQJANDUQLZCBQP-UHFFFAOYSA-N FC=1N=CN(C=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC=1N=CN(C=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C JQJANDUQLZCBQP-UHFFFAOYSA-N 0.000 claims 2
- VQUSEGRUBNQBQO-MJGOQNOKSA-N F[C@@H]1C(NC(C[C@H]1N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@H]1N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O)(C)C)(C)C VQUSEGRUBNQBQO-MJGOQNOKSA-N 0.000 claims 2
- HCJOFNWJQQERIO-UHFFFAOYSA-N N1=C(C=CC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=C(C=CC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C HCJOFNWJQQERIO-UHFFFAOYSA-N 0.000 claims 2
- NUTFYUSFWMPLCN-UHFFFAOYSA-N N1=C(C=NC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=C(C=NC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C NUTFYUSFWMPLCN-UHFFFAOYSA-N 0.000 claims 2
- FHQBSEMQUDGOFL-UHFFFAOYSA-N N1=CC(=CC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=CC(=CC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C FHQBSEMQUDGOFL-UHFFFAOYSA-N 0.000 claims 2
- UEDXZYBNXOLLJU-UHFFFAOYSA-N N1=CC(=CC=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=CC(=CC=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C UEDXZYBNXOLLJU-UHFFFAOYSA-N 0.000 claims 2
- XHXBXPTZXXFGET-UHFFFAOYSA-N N1=CC=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=CC=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C XHXBXPTZXXFGET-UHFFFAOYSA-N 0.000 claims 2
- IRGOXVWPDGHROU-UHFFFAOYSA-N N1=CC=C(C=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=CC=C(C=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C IRGOXVWPDGHROU-UHFFFAOYSA-N 0.000 claims 2
- QOBJXWMTIIAMSS-UHFFFAOYSA-N N1=CN=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=CN=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C QOBJXWMTIIAMSS-UHFFFAOYSA-N 0.000 claims 2
- BTSWOCVDLFYDRA-UHFFFAOYSA-N N1=CN=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=CN=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C BTSWOCVDLFYDRA-UHFFFAOYSA-N 0.000 claims 2
- JODJSEHTXZTFLG-UHFFFAOYSA-N N1=CN=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=CN=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C JODJSEHTXZTFLG-UHFFFAOYSA-N 0.000 claims 2
- WWUWZMDBLQKHFB-UHFFFAOYSA-N N1=NC=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=NC=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C WWUWZMDBLQKHFB-UHFFFAOYSA-N 0.000 claims 2
- XCEUDYHFVIBNGD-UHFFFAOYSA-N N1C(=NC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1C(=NC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C XCEUDYHFVIBNGD-UHFFFAOYSA-N 0.000 claims 2
- GCASEFMNKJJIHC-UHFFFAOYSA-N N1C(C=C(CC1(C)C)C1=COC2=C1N=NC(=C2)C1=CC=C(C=2C=NNC=2)C=C1O)(C)C Chemical compound N1C(C=C(CC1(C)C)C1=COC2=C1N=NC(=C2)C1=CC=C(C=2C=NNC=2)C=C1O)(C)C GCASEFMNKJJIHC-UHFFFAOYSA-N 0.000 claims 2
- UILVXCQQVSAXPF-UHFFFAOYSA-N N1C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=NC=C(C=C1O)C=1C=NNC=1)N=N2)(C)C Chemical compound N1C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=NC=C(C=C1O)C=1C=NNC=1)N=N2)(C)C UILVXCQQVSAXPF-UHFFFAOYSA-N 0.000 claims 2
- BMBROBQQCKNBKO-UHFFFAOYSA-N N1C=CC=2C1=NC=CC=2C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1C=CC=2C1=NC=CC=2C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C BMBROBQQCKNBKO-UHFFFAOYSA-N 0.000 claims 2
- MDFVSCFCOLQXQN-UHFFFAOYSA-N N1C=NC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1C=NC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C MDFVSCFCOLQXQN-UHFFFAOYSA-N 0.000 claims 2
- NQBWYLNVMBFSIN-UHFFFAOYSA-N N1CCC(CC1)C1=CNC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O Chemical compound N1CCC(CC1)C1=CNC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O NQBWYLNVMBFSIN-UHFFFAOYSA-N 0.000 claims 2
- RVAHNMDYQDRSDJ-UHFFFAOYSA-N N1CCC(N2C3=NC=C(N=C3C=N2)C2=CC=C(C=3C=NNC=3)C=C2O)CC1 Chemical compound N1CCC(N2C3=NC=C(N=C3C=N2)C2=CC=C(C=3C=NNC=3)C=C2O)CC1 RVAHNMDYQDRSDJ-UHFFFAOYSA-N 0.000 claims 2
- YADUTMMKNJNEKK-UHFFFAOYSA-N N1N=CC(=C1)C1=C(C=C(C(=C1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)O Chemical compound N1N=CC(=C1)C1=C(C=C(C(=C1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)O YADUTMMKNJNEKK-UHFFFAOYSA-N 0.000 claims 2
- DHHGMXVHXODILS-UHFFFAOYSA-N N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CN2)C=1CC(NC(C=1)(C)C)(C)C Chemical compound N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CN2)C=1CC(NC(C=1)(C)C)(C)C DHHGMXVHXODILS-UHFFFAOYSA-N 0.000 claims 2
- XNYIAFCUBYILSN-UHFFFAOYSA-N N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CS2)C=1CCNCC=1 Chemical compound N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CS2)C=1CCNCC=1 XNYIAFCUBYILSN-UHFFFAOYSA-N 0.000 claims 2
- QUOQKLKFEJLOTO-UHFFFAOYSA-N N=1C=C(N2C=1C=NC=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N=1C=C(N2C=1C=NC=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C QUOQKLKFEJLOTO-UHFFFAOYSA-N 0.000 claims 2
- PCHPVTBEHDYBIV-UHFFFAOYSA-N N=1C=CN2C=1C=C(C=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N=1C=CN2C=1C=C(C=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C PCHPVTBEHDYBIV-UHFFFAOYSA-N 0.000 claims 2
- HEUANYLFLKGBKC-UHFFFAOYSA-N N=1C=CN2C=1C=NC(=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N=1C=CN2C=1C=NC(=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C HEUANYLFLKGBKC-UHFFFAOYSA-N 0.000 claims 2
- MHIYQAQITPPMMQ-UHFFFAOYSA-N N=1C=CN2C=1N=CC(=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N=1C=CN2C=1N=CC(=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C MHIYQAQITPPMMQ-UHFFFAOYSA-N 0.000 claims 2
- WSLLXTMQGQIZNJ-UHFFFAOYSA-N N=1C=CN2N=C(C=CC2=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N=1C=CN2N=C(C=CC2=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C WSLLXTMQGQIZNJ-UHFFFAOYSA-N 0.000 claims 2
- UESVQKLBZITWBV-UHFFFAOYSA-N NC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound NC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C UESVQKLBZITWBV-UHFFFAOYSA-N 0.000 claims 2
- RFGGSEMUUYIZBV-UHFFFAOYSA-N O1C(=NC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound O1C(=NC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C RFGGSEMUUYIZBV-UHFFFAOYSA-N 0.000 claims 2
- OCBJMYXMLGGJSH-UHFFFAOYSA-N O1C=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound O1C=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C OCBJMYXMLGGJSH-UHFFFAOYSA-N 0.000 claims 2
- MYFDSKCZGBAHTG-UHFFFAOYSA-N O1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound O1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C MYFDSKCZGBAHTG-UHFFFAOYSA-N 0.000 claims 2
- XXBPOOJBQVSAAQ-UHFFFAOYSA-N OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C1=CC(N(C=C1)C)=O Chemical compound OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C1=CC(N(C=C1)C)=O XXBPOOJBQVSAAQ-UHFFFAOYSA-N 0.000 claims 2
- URGQSLPAEMPRTI-UHFFFAOYSA-N OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C1=CC(NC=C1)=O Chemical compound OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C1=CC(NC=C1)=O URGQSLPAEMPRTI-UHFFFAOYSA-N 0.000 claims 2
- LXAMQAYMPUSFAV-UHFFFAOYSA-N OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C1=CC(NC=N1)=O Chemical compound OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C1=CC(NC=N1)=O LXAMQAYMPUSFAV-UHFFFAOYSA-N 0.000 claims 2
- KSBURQQFTUIYJH-UHFFFAOYSA-N OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C1=CC=C(N=N1)O Chemical compound OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C1=CC=C(N=N1)O KSBURQQFTUIYJH-UHFFFAOYSA-N 0.000 claims 2
- UZSCCZLIWAKOMJ-UHFFFAOYSA-N OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C1=NC=C(C=N1)O Chemical compound OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C1=NC=C(C=N1)O UZSCCZLIWAKOMJ-UHFFFAOYSA-N 0.000 claims 2
- WEDZOCIMYALXKQ-UHFFFAOYSA-N OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C=1C(=NN(C=1)C)C#N Chemical compound OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C=1C(=NN(C=1)C)C#N WEDZOCIMYALXKQ-UHFFFAOYSA-N 0.000 claims 2
- MAEXIMRWSQWRSA-UHFFFAOYSA-N OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C=1C(=NNC=1)C#N Chemical compound OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C=1C(=NNC=1)C#N MAEXIMRWSQWRSA-UHFFFAOYSA-N 0.000 claims 2
- GHGGQGHLUNPXIO-UHFFFAOYSA-N OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C=1SC(=CN=1)C#N Chemical compound OC=1C=C(C=CC=1C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C=1SC(=CN=1)C#N GHGGQGHLUNPXIO-UHFFFAOYSA-N 0.000 claims 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- HGNVKFMIZLRXNG-UHFFFAOYSA-N C1(NC(CC(C2=CSC3=CC(C4=CC=C(C=5C=NNC=5)C=C4O)=NN=C23)C1)(C)C)(C)C Chemical compound C1(NC(CC(C2=CSC3=CC(C4=CC=C(C=5C=NNC=5)C=C4O)=NN=C23)C1)(C)C)(C)C HGNVKFMIZLRXNG-UHFFFAOYSA-N 0.000 claims 1
- UDAKOGRSNZDUHN-UHFFFAOYSA-N C12CC(CC(CC1)N2)C1=CNC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O Chemical compound C12CC(CC(CC1)N2)C1=CNC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O UDAKOGRSNZDUHN-UHFFFAOYSA-N 0.000 claims 1
- AWMVRQRPJPJTOJ-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CN=CN=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CN=CN=C5)O)C.Cl AWMVRQRPJPJTOJ-UHFFFAOYSA-N 0.000 claims 1
- ARPRJAMVDNNOMT-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NC(=NC=N5)OC)O)C.Cl.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NC(=NC=N5)OC)O)C.Cl.Cl ARPRJAMVDNNOMT-UHFFFAOYSA-N 0.000 claims 1
- DOHWIWKJZVGRLO-UHFFFAOYSA-N CC1=CN=C(S1)C2=CC(=C(C=C2)C3=NN=C4C(=C3)N=NN4C5CC(NC(C5)(C)C)(C)C)O.Cl Chemical compound CC1=CN=C(S1)C2=CC(=C(C=C2)C3=NN=C4C(=C3)N=NN4C5CC(NC(C5)(C)C)(C)C)O.Cl DOHWIWKJZVGRLO-UHFFFAOYSA-N 0.000 claims 1
- XZMKNTZTVAGYFH-UHFFFAOYSA-N CN(C1=CC=C(C=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C Chemical compound CN(C1=CC=C(C=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C XZMKNTZTVAGYFH-UHFFFAOYSA-N 0.000 claims 1
- NMLSGBBRNRYDPQ-UHFFFAOYSA-N COC1=CC(=NC=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound COC1=CC(=NC=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C NMLSGBBRNRYDPQ-UHFFFAOYSA-N 0.000 claims 1
- AGMDABBTPJPSBL-UHFFFAOYSA-N Cl.CC1=NC2=C(N=NC(=C2)C2=C(C=C(C=C2)C=2C=NNC=2)O)N1C1CC(NC(C1)(C)C)(C)C Chemical compound Cl.CC1=NC2=C(N=NC(=C2)C2=C(C=C(C=C2)C=2C=NNC=2)O)N1C1CC(NC(C1)(C)C)(C)C AGMDABBTPJPSBL-UHFFFAOYSA-N 0.000 claims 1
- HFBKNGRWUHFVPQ-UGKGYDQZSA-N F[C@@H]1C(NC(C[C@@H]1N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC(N(C=C1)C)=O)O)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC(N(C=C1)C)=O)O)(C)C)(C)C HFBKNGRWUHFVPQ-UGKGYDQZSA-N 0.000 claims 1
- DKNQRBOACKPKCF-RXVVDRJESA-N F[C@@H]1C(NC(C[C@@H]1N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC(N(C=N1)C)=O)O)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC(N(C=N1)C)=O)O)(C)C)(C)C DKNQRBOACKPKCF-RXVVDRJESA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- BHNGOLBLNBLFDX-UHFFFAOYSA-N N1N=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1N=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C BHNGOLBLNBLFDX-UHFFFAOYSA-N 0.000 claims 1
- OYUZGZPXJAMKJN-UHFFFAOYSA-N N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CN2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CN2)C1CC(NC(C1)(C)C)(C)C OYUZGZPXJAMKJN-UHFFFAOYSA-N 0.000 claims 1
- MJTJPEAXZOVPOK-UHFFFAOYSA-N OC1=C(C=CC(=C1)C=1C=NNC=1)C1=CC2=C(N=N1)N(C(=N2)O)C1CC(NC(C1)(C)C)(C)C Chemical compound OC1=C(C=CC(=C1)C=1C=NNC=1)C1=CC2=C(N=N1)N(C(=N2)O)C1CC(NC(C1)(C)C)(C)C MJTJPEAXZOVPOK-UHFFFAOYSA-N 0.000 claims 1
- LNAFRHAHLZMSDN-WGOQTCKBSA-N O\N=C\1/CCC2=CC(=C(C=C/12)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound O\N=C\1/CCC2=CC(=C(C=C/12)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C LNAFRHAHLZMSDN-WGOQTCKBSA-N 0.000 claims 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690653P | 2018-06-27 | 2018-06-27 | |
| PCT/US2019/038889 WO2020005873A1 (en) | 2018-06-27 | 2019-06-25 | Heterocyclic and heteroaryl compounds for treating huntington's disease |
| EP19736566.1A EP3814357B1 (en) | 2018-06-27 | 2019-06-25 | Heterocyclic and heteroaryl compounds for treating huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240935T1 true HRP20240935T1 (hr) | 2024-11-22 |
Family
ID=67180896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240935TT HRP20240935T1 (hr) | 2018-06-27 | 2019-06-25 | Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11858941B2 (enExample) |
| EP (2) | EP4434990B1 (enExample) |
| JP (1) | JP7421507B2 (enExample) |
| KR (1) | KR102823158B1 (enExample) |
| CN (1) | CN112654625B (enExample) |
| AR (1) | AR119651A1 (enExample) |
| AU (2) | AU2019294478B2 (enExample) |
| BR (1) | BR112020026545A2 (enExample) |
| CA (1) | CA3103976A1 (enExample) |
| CL (3) | CL2020003378A1 (enExample) |
| CO (1) | CO2020016285A2 (enExample) |
| DK (1) | DK3814357T3 (enExample) |
| EA (1) | EA202092896A1 (enExample) |
| ES (1) | ES2983003T3 (enExample) |
| FI (1) | FI3814357T3 (enExample) |
| HR (1) | HRP20240935T1 (enExample) |
| HU (1) | HUE068060T2 (enExample) |
| IL (1) | IL279688B2 (enExample) |
| LT (1) | LT3814357T (enExample) |
| MX (1) | MX2020014098A (enExample) |
| PE (1) | PE20211378A1 (enExample) |
| PL (1) | PL3814357T3 (enExample) |
| PT (1) | PT3814357T (enExample) |
| RS (1) | RS65727B1 (enExample) |
| SG (1) | SG11202012674PA (enExample) |
| SI (1) | SI3814357T1 (enExample) |
| SM (1) | SMT202400286T1 (enExample) |
| UA (1) | UA129258C2 (enExample) |
| WO (1) | WO2020005873A1 (enExample) |
| ZA (1) | ZA202100208B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3119019C (en) | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| EP4151627A1 (en) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| WO2019126731A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| WO2020163248A1 (en) | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| WO2020163541A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| KR102913697B1 (ko) | 2019-02-05 | 2026-01-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| KR102925385B1 (ko) | 2019-02-06 | 2026-02-11 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| JP2022525417A (ja) * | 2019-03-15 | 2022-05-13 | スカイホーク・セラピューティクス・インコーポレーテッド | 異常スプライシングを修正するための組成物および方法 |
| CA3139821A1 (en) * | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| TW202131920A (zh) * | 2019-11-01 | 2021-09-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
| AU2021228284A1 (en) * | 2020-02-28 | 2022-09-29 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| MX2022012575A (es) * | 2020-04-09 | 2023-01-24 | Ptc Therapeutics Inc | Compuestos para usarse para tratar la enfermedad de huntington. |
| WO2021231571A1 (en) | 2020-05-13 | 2021-11-18 | Chdi Foundation, Inc. | Htt modulators for treating huntington's disease |
| MX2023000168A (es) | 2020-07-02 | 2023-04-20 | Remix Therapeutics Inc | Derivados de 2-(indazol-5-il)-6-(piperidin-4-il)-1,7-naftiridina y compuestos relacionados como moduladores para el corte y empalme de ácidos nucleicos y para el tratamiento de enfermedades proliferativas. |
| EP4178963A1 (en) | 2020-07-02 | 2023-05-17 | Remix Therapeutics Inc. | 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| WO2022060951A1 (en) * | 2020-09-16 | 2022-03-24 | Skyhawk Therapeutics, Inc. | Compositions for modulating splicing |
| WO2022060944A1 (en) * | 2020-09-16 | 2022-03-24 | Skyhawk Therapeutics, Inc. | Compositions for modulating splicing |
| WO2022060943A1 (en) * | 2020-09-16 | 2022-03-24 | Skyhawk Therapeutics, Inc. | Compositions for modulating splicing |
| EP4244362A1 (en) | 2020-11-12 | 2023-09-20 | PTC Therapeutics, Inc. | Novel rna transcript |
| EP4649945A1 (en) * | 2020-11-13 | 2025-11-19 | PTC Therapeutics, Inc. | Tablet for use in treating huntington's disease and method of making the same |
| EP4308572B1 (en) * | 2021-03-17 | 2025-04-23 | F. Hoffmann-La Roche AG | New thienopyrimidinone derivatives |
| TW202304446A (zh) | 2021-03-29 | 2023-02-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
| CN118159539A (zh) * | 2021-07-30 | 2024-06-07 | Ptc医疗公司 | 用于治疗亨廷顿氏病的杂芳基化合物 |
| EP4426702A1 (en) * | 2021-11-04 | 2024-09-11 | Skyhawk Therapeutics, Inc. | Condensed-pyrazine amine derivatives for treating sca3 |
| AU2022394333A1 (en) | 2021-11-17 | 2024-06-27 | Chdi Foundation, Inc. | HTT modulators for treating Huntington’s disease |
| AU2023270000A1 (en) * | 2022-05-10 | 2024-11-28 | Foghorn Therapeutics Inc. | Pyrazine derivatives and uses thereof |
| CA3249778A1 (en) * | 2022-06-15 | 2023-12-21 | Ptc Therapeutics, Inc. | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE |
| CN120152974A (zh) | 2022-10-26 | 2025-06-13 | 天维生物制药有限公司 | 缩环哒嗪衍生物 |
| CN120569372A (zh) | 2023-01-24 | 2025-08-29 | 第一三共株式会社 | 经取代的苯化合物 |
| AU2024268627A1 (en) * | 2023-05-09 | 2025-10-02 | Ptc Therapeutics, Hd, Inc. | Crystalline forms of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3h-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2h-1,2,3-triazol-2-yl)phenol |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
| EP4719386A2 (en) * | 2023-06-02 | 2026-04-08 | Merck Sharp & Dohme LLC | 5,6 saturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3 |
| WO2025040014A1 (zh) * | 2023-08-18 | 2025-02-27 | 英矽智能科技知识产权有限公司 | 并环化合物及其制备方法和用途 |
| TW202617152A (zh) | 2024-06-20 | 2026-05-01 | 美商Ｐｔｃ治療公司 | 杭丁頓氏舞蹈症的治療 |
Family Cites Families (194)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL297170A (enExample) | 1963-04-04 | 1900-01-01 | ||
| US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| GB1383409A (en) | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
| US4122274A (en) | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| JPS56150091A (en) | 1980-03-28 | 1981-11-20 | Janssen Pharmaceutica Nv | 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture |
| US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| FR2567518B1 (fr) | 1984-07-11 | 1987-11-13 | Sanofi Sa | Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5599816A (en) | 1990-05-02 | 1997-02-04 | Abbott Laboratories | Quinolizinone type compounds |
| EP0640083A1 (en) | 1992-05-13 | 1995-03-01 | E.I. Du Pont De Nemours And Company | Substituted pyrido 1,2-a]pyrimidinone derivatives as fungicides |
| ATE368107T1 (de) | 1993-05-11 | 2007-08-15 | Univ North Carolina | Antisense oligonukleotide die anomales splicing verhindern und deren verwendung |
| KR19990022524A (ko) | 1995-06-06 | 1999-03-25 | 웨인스톡 스티븐 에프. | 퀴놀리지논형화합물 |
| US5916916A (en) | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| CA2269561C (en) | 1998-04-22 | 2007-06-05 | Dainippon Ink And Chemicals, Inc. | Naphthalene derivative and liquid crystal composition comprising the same |
| HK1040076A1 (zh) | 1998-09-21 | 2002-05-24 | 希雷生物化学有限公司 | 作为整联蛋白抑制剂的喹嗪酮 |
| US6172216B1 (en) | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
| EP1227084B1 (en) | 1999-10-28 | 2005-12-14 | Trine Pharmaceuticals, Inc. | Drug discharge pump inhibitors |
| ATE363471T1 (de) | 2000-01-24 | 2007-06-15 | Astrazeneca Ab | Durch einen morpholinrest substituierte therapeutische verbindungen |
| US20050054836A1 (en) | 2000-11-09 | 2005-03-10 | Cold Spring Harbor Laboratory | Chimeric molecules to modulate gene expression |
| US6774134B2 (en) | 2000-12-20 | 2004-08-10 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
| BR0116493A (pt) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| JPWO2002087589A1 (ja) | 2001-04-26 | 2004-08-12 | 第一製薬株式会社 | 薬剤排出ポンプ阻害薬 |
| ATE466581T1 (de) | 2001-12-07 | 2010-05-15 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| EP1542667B1 (en) | 2002-07-24 | 2012-03-07 | PTC Therapeutics, Inc. | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| US7423133B2 (en) | 2002-08-23 | 2008-09-09 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescent glycosides and methods for their use |
| DE60311853T2 (de) | 2002-09-30 | 2007-06-21 | Neurosearch A/S | Neue 1,4-diazabicycloalkanderivate, deren herstellung und verwendung |
| US20070078144A1 (en) | 2003-01-29 | 2007-04-05 | Stockwell Brent R | Agents for treating neurodegenerative diseases |
| ES2339862T3 (es) | 2003-06-20 | 2010-05-26 | Novartis Vaccines And Diagnostics, Inc. | Compuestos de piridino 1,2-a-pirimidin-4-ona como agentes anticancerosos. |
| GB0315494D0 (en) | 2003-07-02 | 2003-08-06 | Biofocus Plc | Compounds which bind to the active site of protein kinase enzymes |
| BRPI0413234A (pt) | 2003-08-01 | 2006-10-03 | Genelabs Tech Inc | derivados de imidazola bicìclica contra flaviviridae |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
| US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US20050137203A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
| US7309699B2 (en) | 2003-12-22 | 2007-12-18 | Abbott Laboratories | 3-Quinuclidinyl amino-substituted biaryl derivatives |
| US7655657B2 (en) | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| CA2551178C (en) | 2003-12-24 | 2012-11-06 | Biota Scientific Management Pty Ltd | Polycyclic agents for the treatment of respiratory syncytial virus infections |
| SE0400184D0 (sv) | 2004-01-30 | 2004-01-30 | Fyrkloevern Scandinavia Ab | New therapeutical use |
| TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| CN1964717A (zh) | 2004-04-08 | 2007-05-16 | 神经能质公司 | 经取代∴啉－4－基胺 |
| WO2005105801A1 (en) | 2004-05-04 | 2005-11-10 | Warner-Lambert Company Llc | Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents |
| US7399767B2 (en) | 2005-01-21 | 2008-07-15 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| US7879992B2 (en) | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| JP2006219453A (ja) | 2005-02-14 | 2006-08-24 | Tokyo Univ Of Pharmacy & Life Science | キノリン環を母核とする金属識別型二波長性蛍光分子 |
| US7563601B1 (en) | 2005-06-01 | 2009-07-21 | City Of Hope | Artificial riboswitch for controlling pre-mRNA splicing |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| CN103110635A (zh) | 2005-07-04 | 2013-05-22 | 海波因特制药有限责任公司 | 组胺h3受体拮抗剂 |
| US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
| US8258109B2 (en) | 2005-10-20 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of LMNA expression |
| WO2007058894A2 (en) | 2005-11-10 | 2007-05-24 | The University Of North Carolina At Chapel Hill | Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
| CA2632642A1 (en) | 2005-12-06 | 2007-06-14 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
| JP2009520700A (ja) | 2005-12-21 | 2009-05-28 | ペインセプター ファーマ コーポレーション | 依存性イオンチャネルを調節するための組成物および方法 |
| EP2422819B1 (en) | 2006-01-26 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
| EP2388328A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| NZ570524A (en) | 2006-03-28 | 2011-08-26 | High Point Pharmaceuticals Llc | Benzothiazoles having histamine H3 receptor activity |
| WO2007130383A2 (en) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
| US20080247964A1 (en) | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
| WO2007133756A2 (en) * | 2006-05-15 | 2007-11-22 | Neurogen Corporation | Crf1 receptor ligands comprising heteroaryl fused bicycles |
| JP2009537599A (ja) | 2006-05-23 | 2009-10-29 | ノイロサーチ アクティーゼルスカブ | 新規８，１０−ジアザ−ビシクロ［４．３．１］デカン誘導体及びそれらの医学的使用 |
| EP2079724B1 (en) | 2006-07-20 | 2010-05-26 | Amgen Inc. | Substituted pyridone compounds and methods of use |
| US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| US7994181B2 (en) | 2006-08-03 | 2011-08-09 | Rottapharm S.P.A. | 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents |
| EP2079734A1 (en) | 2006-10-25 | 2009-07-22 | NeuroSearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| AR064517A1 (es) | 2006-12-22 | 2009-04-08 | Avexa Ltd | Pirimidinionas biciclicas y sus usos |
| US20080171792A1 (en) | 2006-12-28 | 2008-07-17 | Jobdevairakkam Christopher New | Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders |
| FR2914188B1 (fr) | 2007-03-28 | 2012-06-22 | Trophos | Nouvelle composition a base d'oxime de cholest-4-en-3-one |
| EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
| DK2193133T3 (en) | 2007-09-27 | 2015-10-05 | Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii | IMIDAZOLOTHIADIAZOLES USED AS PROTEINKINASE INHIBITORS |
| CA2700841A1 (en) | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| US8153813B2 (en) | 2007-12-20 | 2012-04-10 | Abbott Laboratories | Benzothiazole and benzooxazole derivatives and methods of use |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| US20090258907A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | Compounds useful as inhibitors of rock kinases |
| WO2009131958A2 (en) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising triazine derivatives |
| US8633019B2 (en) | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| BRPI0822462A2 (pt) | 2008-06-20 | 2015-10-13 | Rottapharm Spa | derivados de 6-1h-imidazo-quinazolina e de quinolinas, novos inibidores de mao e ligantes a receptor de imidazolina. |
| EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| US8318732B2 (en) | 2008-07-02 | 2012-11-27 | Avexa Limited | Compounds having antiviral properties |
| WO2010019236A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc | Methods for treating spinal muscular atrophy |
| WO2010024903A1 (en) | 2008-08-29 | 2010-03-04 | Yangbo Feng | BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS |
| EP2350067A2 (en) | 2008-10-16 | 2011-08-03 | Schering Corporation | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2010071819A1 (en) | 2008-12-19 | 2010-06-24 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
| AU2010214101A1 (en) | 2009-02-11 | 2011-09-01 | Sunovion Pharmaceuticals Inc. | Histamine H3 inverse agonists and antagonists and methods of use thereof |
| FR2945289A1 (fr) | 2009-05-11 | 2010-11-12 | Sanofi Aventis | Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique |
| WO2010145208A1 (en) | 2009-06-19 | 2010-12-23 | Abbott Laboratories | Diazahomoadamantane derivatives and methods of use thereof |
| EP3626823A1 (en) | 2009-09-11 | 2020-03-25 | Ionis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| US20150018301A1 (en) | 2009-11-06 | 2015-01-15 | The Johns Hopkins University | LRRK-2-Mediated Neuronal Toxicity |
| EP2501231B1 (en) | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| KR20130088002A (ko) | 2010-01-13 | 2013-08-07 | 재단법인 한국파스퇴르연구소 | 항-감염성 피리도(1,2-ａ)피리미딘 |
| ES2733708T3 (es) | 2010-02-08 | 2019-12-02 | Ionis Pharmaceuticals Inc | Reducción selectiva de variantes alélicas |
| EP2536738A4 (en) | 2010-02-08 | 2014-09-17 | Isis Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OR SUFFERING IN CONNECTION WITH REPEAT EXTENSIONS |
| JP6018506B2 (ja) | 2010-02-08 | 2016-11-02 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 対立遺伝子多様体の選択的低減 |
| CA2800509A1 (en) | 2010-05-24 | 2011-12-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| ES2756326T3 (es) | 2010-07-19 | 2020-04-27 | Ionis Pharmaceuticals Inc | Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK) |
| WO2012019106A2 (en) | 2010-08-06 | 2012-02-09 | Board Of Regents Of The University Of Nebraska | Positive and negative modulators of nmda receptors |
| WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
| CN102617548A (zh) * | 2011-01-31 | 2012-08-01 | 北京赛林泰医药技术有限公司 | 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用 |
| WO2012104823A2 (en) | 2011-02-04 | 2012-08-09 | Novartis Ag | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases |
| US10017764B2 (en) | 2011-02-08 | 2018-07-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| US9447075B2 (en) | 2011-08-02 | 2016-09-20 | The Brigham And Women's Hospital, Inc. | Pyridazine derivatives as EAAT2 activators |
| US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| US20140303235A1 (en) | 2011-08-11 | 2014-10-09 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
| US20130046093A1 (en) | 2011-08-18 | 2013-02-21 | Korea Institute Of Science And Technology | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same |
| EP2751269B1 (en) | 2011-08-29 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| US9662314B2 (en) | 2011-10-21 | 2017-05-30 | Tufts Medical Center, Inc. | Compounds and methods for the treatment of muscular disease, and related screening methods |
| GB201119538D0 (en) | 2011-11-10 | 2011-12-21 | Viral Ltd | Pharmaceutical compounds |
| CA2856334A1 (en) | 2011-11-28 | 2013-06-06 | Christina Hebach | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| MX352861B (es) | 2011-12-30 | 2017-12-13 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| MX357834B (es) | 2012-01-26 | 2018-07-26 | Ptc Therapeutics Inc | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. |
| EP3406252B1 (en) | 2012-02-10 | 2020-05-13 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| US9371336B2 (en) | 2012-03-01 | 2016-06-21 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP2828247B1 (en) | 2012-03-23 | 2019-01-16 | PTC Therapeutics, Inc. | 4h-chromen-4-one derivatives for treating spinal muscular atrophy |
| SG11201406584TA (en) * | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| US9212209B2 (en) | 2012-07-13 | 2015-12-15 | Indiana University Research And Technology Corporation | Screening methods for spinal muscular atrophy |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| EP2906255B1 (en) | 2012-10-12 | 2023-02-22 | Ionis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
| EP4086347A3 (en) | 2012-10-12 | 2023-01-11 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| US9227976B2 (en) * | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| CA2889494C (en) | 2012-10-25 | 2018-12-18 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| JP6255711B2 (ja) | 2012-11-01 | 2018-01-10 | 株式会社リコー | エレクトロクロミック化合物、エレクトロクロミック組成物及び表示素子 |
| US9040712B2 (en) | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
| EP2951304B1 (en) | 2013-02-04 | 2020-07-08 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| CA2903903C (en) | 2013-03-05 | 2021-05-04 | Merck Patent Gmbh | Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer |
| JP2016518421A (ja) | 2013-05-14 | 2016-06-23 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 呼吸器合胞体ウイルス感染症の処置および予防のためのアザ−オキソ−インドール |
| CA2913785C (en) | 2013-06-25 | 2021-08-31 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| CN105636953B (zh) | 2013-07-31 | 2018-01-02 | 诺华股份有限公司 | 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途 |
| CA2915764A1 (en) | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| WO2015095446A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| WO2015095449A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount rna transcripts |
| WO2015105657A1 (en) | 2013-12-19 | 2015-07-16 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| US9624170B2 (en) * | 2013-12-26 | 2017-04-18 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors |
| EP3094728B1 (en) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Chiral design |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| AR099134A1 (es) | 2014-01-24 | 2016-06-29 | Hoffmann La Roche | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina |
| CN106103416B (zh) | 2014-03-14 | 2021-03-02 | 拉夸里亚创药株式会社 | 作为trpm8拮抗剂的氮杂螺衍生物 |
| CN106573880B (zh) | 2014-03-19 | 2019-07-30 | 阿米达斯公司 | 淀粉样蛋白靶向剂及其使用方法 |
| AU2015261046C1 (en) | 2014-05-15 | 2019-07-25 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| US20170121197A1 (en) | 2014-06-17 | 2017-05-04 | Novozymes A/S | Biological Phosphorus Removal from Wastewater |
| MX375925B (es) | 2014-06-25 | 2025-03-07 | Hoffmann La Roche | Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. |
| CN107207526A (zh) | 2014-12-02 | 2017-09-26 | 拜耳作物科学股份公司 | 作为害虫防治剂的双环化合物 |
| AU2015370903B2 (en) | 2014-12-24 | 2021-06-17 | Uniqure Ip B.V. | RNAi induced huntingtin gene suppression |
| CA3199430A1 (en) | 2015-01-16 | 2016-07-21 | The General Hospital Corporation | Compounds for improving mrna splicing |
| EP3256126B1 (en) | 2015-02-09 | 2024-03-27 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
| GB201502567D0 (en) | 2015-02-16 | 2015-04-01 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CN107635984B (zh) | 2015-03-11 | 2021-04-13 | Fmc公司 | 杂环取代的二环唑杀有害生物剂 |
| GB201506933D0 (en) | 2015-04-23 | 2015-06-10 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| CN117965536A (zh) | 2015-07-22 | 2024-05-03 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| WO2017023987A1 (en) * | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| AU2016353961B2 (en) | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
| AR106652A1 (es) | 2015-11-12 | 2018-02-07 | Hoffmann La Roche | Compuestos para tratar la esclerosis lateral amiotrófica |
| US10383867B2 (en) | 2015-11-28 | 2019-08-20 | Russell Dahl | Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders |
| CA3119019C (en) * | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| EP3386978B1 (en) | 2015-12-10 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bridged piperidine derivatives |
| US10526345B2 (en) | 2016-04-08 | 2020-01-07 | Mankind Pharma Ltd. | Compounds as GPR119 agonists |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| EP3452596A4 (en) | 2016-05-04 | 2020-03-18 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
| WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
| US20190264267A1 (en) | 2016-07-25 | 2019-08-29 | Wave Life Sciences Ltd. | Phasing |
| TW202500565A (zh) * | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| US11857599B2 (en) | 2017-04-03 | 2024-01-02 | Acceleron Pharma Inc. | Compositions and methods for treating spinal muscular atrophy |
| US11591336B2 (en) * | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
| EP4151627A1 (en) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| WO2019165073A1 (en) | 2018-02-21 | 2019-08-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| US12138263B2 (en) * | 2018-03-21 | 2024-11-12 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof |
| CN117263942A (zh) * | 2018-03-21 | 2023-12-22 | 传达治疗有限公司 | Shp2磷酸酶抑制剂及其使用方法 |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| JP2022525417A (ja) | 2019-03-15 | 2022-05-13 | スカイホーク・セラピューティクス・インコーポレーテッド | 異常スプライシングを修正するための組成物および方法 |
| CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| WO2021007378A1 (en) | 2019-07-11 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for use in treating huntington's disease |
| TW202131920A (zh) | 2019-11-01 | 2021-09-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
| MX2022012575A (es) | 2020-04-09 | 2023-01-24 | Ptc Therapeutics Inc | Compuestos para usarse para tratar la enfermedad de huntington. |
| EP4244362A1 (en) | 2020-11-12 | 2023-09-20 | PTC Therapeutics, Inc. | Novel rna transcript |
| CN118159539A (zh) | 2021-07-30 | 2024-06-07 | Ptc医疗公司 | 用于治疗亨廷顿氏病的杂芳基化合物 |
-
2019
- 2019-06-25 IL IL279688A patent/IL279688B2/en unknown
- 2019-06-25 SI SI201930785T patent/SI3814357T1/sl unknown
- 2019-06-25 DK DK19736566.1T patent/DK3814357T3/da active
- 2019-06-25 JP JP2020572895A patent/JP7421507B2/ja active Active
- 2019-06-25 HU HUE19736566A patent/HUE068060T2/hu unknown
- 2019-06-25 MX MX2020014098A patent/MX2020014098A/es unknown
- 2019-06-25 SG SG11202012674PA patent/SG11202012674PA/en unknown
- 2019-06-25 WO PCT/US2019/038889 patent/WO2020005873A1/en not_active Ceased
- 2019-06-25 CN CN201980051041.4A patent/CN112654625B/zh active Active
- 2019-06-25 UA UAA202008291A patent/UA129258C2/uk unknown
- 2019-06-25 PE PE2020002185A patent/PE20211378A1/es unknown
- 2019-06-25 PT PT197365661T patent/PT3814357T/pt unknown
- 2019-06-25 AU AU2019294478A patent/AU2019294478B2/en active Active
- 2019-06-25 PL PL19736566.1T patent/PL3814357T3/pl unknown
- 2019-06-25 FI FIEP19736566.1T patent/FI3814357T3/fi active
- 2019-06-25 RS RS20240779A patent/RS65727B1/sr unknown
- 2019-06-25 KR KR1020207036440A patent/KR102823158B1/ko active Active
- 2019-06-25 HR HRP20240935TT patent/HRP20240935T1/hr unknown
- 2019-06-25 EP EP24168248.3A patent/EP4434990B1/en active Active
- 2019-06-25 EP EP19736566.1A patent/EP3814357B1/en active Active
- 2019-06-25 SM SM20240286T patent/SMT202400286T1/it unknown
- 2019-06-25 LT LTEPPCT/US2019/038889T patent/LT3814357T/lt unknown
- 2019-06-25 ES ES19736566T patent/ES2983003T3/es active Active
- 2019-06-25 US US17/254,660 patent/US11858941B2/en active Active
- 2019-06-25 BR BR112020026545-4A patent/BR112020026545A2/pt unknown
- 2019-06-25 CA CA3103976A patent/CA3103976A1/en active Pending
- 2019-06-25 EA EA202092896A patent/EA202092896A1/ru unknown
- 2019-06-28 AR ARP190101808A patent/AR119651A1/es active IP Right Grant
-
2020
- 2020-12-23 CL CL2020003378A patent/CL2020003378A1/es unknown
- 2020-12-24 CO CONC2020/0016285A patent/CO2020016285A2/es unknown
-
2021
- 2021-01-12 ZA ZA2021/00208A patent/ZA202100208B/en unknown
- 2021-11-16 CL CL2021003022A patent/CL2021003022A1/es unknown
-
2022
- 2022-12-02 CL CL2022003434A patent/CL2022003434A1/es unknown
-
2023
- 2023-05-23 AU AU2023203241A patent/AU2023203241B2/en active Active
-
2025
- 2025-09-30 US US19/344,653 patent/US20260028347A1/en active Pending